Skip to Content

Press Release

Tiziana Life Sci PLC - 9th Annual LD Micro Invitational

May 28, 2019 at 2:00 AM EDT
RNS Number : 2217A
Tiziana Life Sciences PLC
28 May 2019
 

 

Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational 

 

New York / LondonMay 28, 2018  Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications,  today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4, 2019 at 11:20 AM PST / 2:20 PM EST. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences will be presenting and meeting with investors.

 

"We look  forward to presenting our very recent clinical and corporate advancements at LD Micro. Interim results from our Phase 2a trial with one of our lead drug candidates, Milciclib, in advanced liver cancer demonstrated encouraging results, as we look ahead to announce top line results in the third quarter of 2019. Our clinical development pipeline includes Milciclib and Foralumab, the world's first fully human anti-CD3 monoclonal antibody" Kunwar Shailubhai stated.

 

"This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever growing community."

 

The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.

 

View Tiziana Life Sciences' profile here: http://www.ldmicro.com/profile/TLSA 

 

 

 

About Tiziana Life Sciences

 

Tiziana Life Sciences (NASDAQ: TLSA) is a clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Tiziana's two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Through previous Phase II trials, both drug candidates have been de-risked by demonstration of both safety and efficacy in humans. Foralumab is the world's first and only fully human anti-CD3 monoclonal antibody. This is a substantial advantage over similar antibody drugs which are sourced from mice and therefore cause unwanted immune responses in humans. Tiziana is a market leader in the invention of oral and nasal delivery methods for its drugs, creating treatments that are potentially more effective and safer than IV delivery.  Tiziana has a robust and growing patent portfolio.

 

About LD Micro

 

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

 

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

 

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.


For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

 

 

Source: Tiziana Life Sciences via LD Micro

 

  

For further enquiries:

 

Tiziana Life Sciences plc                                                                +44 (0)20 7493 2853

Tiziano Lazzaretti, Chief Financial Officer                               

 

 

Cairn Financial Advisers LLP (Nominated adviser)                     +44 (0)20 7213 0883

Liam Murray / Jo Turner

 

Stockdale Securities Limited (Broker)

Andy Crossley / Antonio Bossi

 

  +44 (0)20 7601 6125

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKODBFBKDQPB